Abstract：
This year marks the tenth anniversary of the world\'s first transplantation of tissue generated from induced pluripotent stem cells (iPSCs). There is now a growing number of clinical trials worldwide examining the efficacy and safety of autologous and allogeneic iPSC-derived products for treating various pathologic conditions. As we patiently wait for the results from these and future clinical trials, it is imperative to strategize for the next generation of iPSC-based therapies. This review examines the lessons learned from the development of another advanced cell therapy, chimeric antigen receptor (CAR) T cells, and the possibility of incorporating various new bioengineering technologies in development, from RNA engineering to tissue fabrication, to apply iPSCs not only as a means to achieve personalized medicine but also as designer medical applications.
摘要：
今年是世界上首次由诱导多能干细胞（iPSCs）产生的组织移植十周年。现在全世界有越来越多的临床试验检查自体和同种异体iPSC衍生产品用于治疗各种病理状况的功效和安全性。当我们耐心等待这些和未来临床试验的结果时，为下一代基于iPSC的疗法制定战略势在必行。这篇综述探讨了从另一种先进的细胞疗法的发展中学到的经验教训，嵌合抗原受体（CAR）T细胞，以及将各种新的生物工程技术纳入开发的可能性，从RNA工程到组织制造，应用iPSCs不仅是实现个性化医疗的手段，也是设计医疗应用。
